Oruka Therapeutics Expands IL-23 Drug Rights But Delays Key IBD Trial
NEW YORK, June 2 —
Oruka Therapeutics widened its IL-23 indication rights in a pipeline update that simultaneously pushed back its IBD dosing timeline, stripping away the near-term catalyst investors were pricing in.
- ORKA shares trade at $55.39, carrying a -22.5x forward P/E — a valuation that assumes the pipeline delivers, not stalls
- Piper Sandler reaffirmed its Overweight rating, suggesting the sell-side sees the IL-23 expansion as net positive despite the IBD slip
- Watch for: a revised IBD dosing start date, which is now the single catalyst that can reset the narrative
What Actually Happened
Oruka's IL-23 rights expansion is a structural upgrade to the asset, not just a headline. IL-23 inhibition is already a validated mechanism — dupilumab and risankizumab have proven the pathway across dermatology and gastroenterology — so broader indication rights mean Oruka can pursue more addressable markets with a biology the FDA understands. That is the kind of optionality that shows up in a terminal value model, not next quarter's earnings. The catch is that optionality is worthless without execution, and the IBD delay is the first sign that execution is running behind.
The Catch
A negative forward P/E tells you the market is paying for future cash flows that do not yet exist. When you delay the trial that was supposed to demonstrate progress toward those cash flows, you are not just moving a date — you are widening the gap between current price and any fundamental justification for it. The IBD delay removes a concrete milestone and replaces it with a blank calendar entry. Until Oruka discloses a new dosing start date, the stock has no near-term trigger to close that gap.
Bottom Line
This update makes ORKA more interesting for long-duration growth investors and less interesting for anyone who needed a 2025 catalyst to stay in the trade. The IL-23 rights expansion is genuinely additive to the long-term story; Piper Sandler's Overweight hold is not a rubber stamp. But the stock is priced for a pipeline that executes on schedule, and IBD is now off-schedule. The one number to watch is the revised IBD dosing start date — that disclosure will tell you whether this is a minor slip or something more structural.
Generate a full Oruka Therapeutics report, including pipeline analysis and comparable biotech valuations, at Basis Report for ORKA.
Basis Report does not hold positions in securities discussed. This is not investment advice.